CSL completed the acquisition of Vifor Pharma for $11.7bn.

CSL, a biotechnology company, completed the acquisition of Vifor Pharma, a pharmaceuticals company, for $11.7bn. “Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies. The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders," Jacques Theurillat, Vifor Pharma Chairman. On January 18, 2022, CSL published offer prospectus on public tender offer for all publicly held shares of Vifor Pharma.